Hidradenitis Suppurativa Treatment Guidelines
Initial Assessment and Treatment
- The American Academy of Dermatology recommends determining Hurley stage by examining the thighs for isolated nodules, recurrent nodules, and extensive sinus tracts, to guide treatment decisions 1, 2
- For mild disease (Hurley Stage I), the American Academy of Dermatology suggests using topical clindamycin 1% solution/gel applied twice daily to all affected thigh areas for 12 weeks, combined with benzoyl peroxide wash or chlorhexidine 4% wash daily to reduce Staphylococcus aureus resistance risk 1, 2
- For moderate disease (Hurley Stage II), the American Academy of Dermatology recommends clindamycin 300 mg orally twice daily PLUS rifampicin 300-600 mg orally once or twice daily for 10-12 weeks, achieving response rates of 71-93% in systematic reviews 1, 2
Treatment Algorithm by Disease Severity
- For severe or refractory disease (Hurley Stage III or failed antibiotics), the American Academy of Dermatology suggests using adalimumab as first-line biologic, with a dosing schedule of 160 mg subcutaneous on day 1, 80 mg subcutaneous on day 15, and 40 mg weekly subcutaneous ongoing 1, 2
- The American Academy of Dermatology recommends assessing response at 12-16 weeks using HiSCR, and considering second-line biologic options such as infliximab, secukinumab, or ustekinumab if adalimumab fails after 16 weeks 1, 2, 5
Mandatory Adjunctive Measures
- The American Academy of Dermatology suggests referring patients for smoking cessation, as tobacco use is associated with dramatically worse outcomes (odds ratio 36) 3
- The American Academy of Dermatology recommends referring patients for weight management if BMI is elevated, as obesity significantly worsens disease (odds ratio 33) and predicts poor antibiotic response 3
Treatment Duration and Monitoring
- The American Academy of Dermatology recommends treating with clindamycin-rifampicin for 10-12 weeks, then considering treatment breaks to assess ongoing need and limit antimicrobial resistance 1, 2
- The American Academy of Dermatology suggests monitoring patients at 12 weeks using objective measures: HiSCR, pain VAS score, inflammatory lesion count, and DLQI quality of life score 2, 3